Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV001004174 | SCV001162991 | likely pathogenic | Rhizomelic chondrodysplasia punctata type 1 | criteria provided, single submitter | clinical testing | ||
Baylor Genetics | RCV003473544 | SCV004203896 | likely pathogenic | Peroxisome biogenesis disorder 9B | 2024-03-22 | criteria provided, single submitter | clinical testing | |
Center for Genomic Medicine, |
RCV003473544 | SCV004805376 | likely pathogenic | Peroxisome biogenesis disorder 9B | 2024-03-25 | criteria provided, single submitter | research | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004702573 | SCV005204057 | uncertain significance | not specified | 2024-06-21 | criteria provided, single submitter | clinical testing | Variant summary: PEX7 c.116A>C (p.His39Pro) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 3.4e-05 in 29772 control chromosomes (gnomAD). c.116A>C has been reported in the literature in an individual affected with Rhizomelic Chondrodysplasia Punctata Type 1 (Braverman_2002). This report does not provide unequivocal conclusions about association of the variant with Rhizomelic Chondrodysplasia Punctata Type 1. At least one publication reports experimental evidence evaluating an impact on protein function, finding that the variant results in impaired import of PTS2 (Braverman_2002). The following publication has been ascertained in the context of this evaluation (PMID: 12325024). ClinVar contains an entry for this variant (Variation ID: 813362). Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. |